OMERS ADMINISTRATION Corp Buys New Stake in GSK PLC Sponsored ADR $GSK

Key Points

• OMERS ADMINISTRATION Corp has acquired a new position in GSK PLC Sponsored ADR, purchasing 76,100 shares valued at approximately $2.948 million in the first quarter of the year.
• GSK recently reported EPS of $1.23 for the last quarter, exceeding expectations, and announced a $0.4206 quarterly dividend, yielding 4.2% annually.
• Despite some analyst upgrades, GSK holds a consensus rating of "Reduce" with a target price of $37.38, indicating sustained caution among investors.

OMERS ADMINISTRATION Corp purchased a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 76,100 shares of the pharmaceutical company's stock, valued at approximately $2,948,000.

Other large investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC grew its stake in shares of GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after acquiring an additional 460 shares during the period. Costello Asset Management INC bought a new stake in shares of GSK in the first quarter worth approximately $31,000. Richardson Financial Services Inc. grew its stake in shares of GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares during the period. Olde Wealth Management LLC bought a new stake in shares of GSK in the first quarter worth approximately $36,000. Finally, Cary Street Partners Investment Advisory LLC grew its stake in shares of GSK by 525.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK stock traded up $0.48 during mid-day trading on Wednesday, hitting $39.44. The stock had a trading volume of 2,842,316 shares, compared to its average volume of 5,083,738. The firm has a market capitalization of $80.32 billion, a P/E ratio of 18.26, a P/E/G ratio of 1.72 and a beta of 0.53. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm's 50 day moving average is $38.43 and its 200 day moving average is $38.28. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.26.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. GSK's quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is 77.78%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GSK shares. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.